Results 101 to 110 of about 414,323 (331)

A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease: Modelling Therapies for Multiple Myeloma Induced Bone Disease [PDF]

open access: yes, 2015
Multiple myeloma bone disease is devastating for patients and a major cause of morbidity. The disease leads to bone destruction by inhibiting osteoblast activity while stimulating osteoclast activity.
Fagan, Michael J.   +2 more
core   +2 more sources

Mapping CSC‐Mediated Ovarian Cancer Chemoresistance via CXCR4‐PET to Guide Precision Cisplatin Re‐Sensitization Therapy

open access: yesAdvanced Science, EarlyView.
CXCR4 functions as a potential cancer stem cell‐associated marker linked to chemoresistance in ovarian cancer, and an inhibitor of CXCR4, AMD3100, can enhance the cytotoxic response to cisplatin. Based on these findings, [68Ga]Ga‐Pentixafor positron emission tomography enables selective visualization of CXCR4‐high ovarian cancer, while AMD3100 combined
Lixia Feng   +12 more
wiley   +1 more source

Spontaneous regression of mantle cell lymphoma: a report of four cases

open access: yesCancer Communications, 2018
Background Spontaneous regression has been reported in some indolent forms of lymphoma. Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm and has a poor prognosis.
Haige Ye   +8 more
doaj   +1 more source

Monoclonal antibodies against human astrocytomas and their reactivity pattern [PDF]

open access: yes, 1987
The establishment of hybridomas after fusion of X63-Ag8.653 mouse myeloma cells and splenocytes from mice hyperimmunized against human astrocytomas is presented. The animals were primed with 5 × 106 chemically modified uncultured or cultured glioma cells.
B. Martin   +36 more
core   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

open access: yesAdvanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo   +5 more
wiley   +1 more source

CXC Chemokine‐Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response

open access: yesAdvanced Science, EarlyView.
Tumor vascular remodeling is discussed from a chemokine‐centered perspective. This review summarizes the bidirectional, temporal, and tissue‐specific roles of CXC chemokines in regulating vascular function and immune accessibility. A functional vascular normalization score is introduced as a conceptual framework to integrate dynamic vascular and immune
Hongdan Chen   +7 more
wiley   +1 more source

Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple : A study of the Korean Multiple Myeloma Working Party (KMM-1909)

open access: gold, 2022
Sung Hoon Jung   +8 more
openalex   +1 more source

Focal Spot, Spring 1979 [PDF]

open access: yes, 1979
https://digitalcommons.wustl.edu/focal_spot_archives/1023/thumbnail ...

core   +1 more source

Artificial Intelligence for Bone: Theory, Methods, and Applications

open access: yesAdvanced Intelligent Discovery, EarlyView.
Advances in artificial intelligence (AI) offer the potential to improve bone research. The current review explores the contributions of AI to pathological study, biomarker discovery, drug design, and clinical diagnosis and prognosis of bone diseases. We envision that AI‐driven methodologies will enable identifying novel targets for drugs discovery. The
Dongfeng Yuan   +3 more
wiley   +1 more source

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

open access: yesHaematologica, 2017
B-cell maturation antigen is expressed on plasma cells. In this study, we have identified serum B-cell maturation antigen as a novel biomarker that can monitor and predict outcomes for multiple myeloma patients.
Michael Ghermezi   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy